New-onset diabetes after transplantation

Curr Diab Rep. 2005 Aug;5(4):300-4. doi: 10.1007/s11892-005-0027-y.

Abstract

New-onset diabetes after transplantation (NODAT) is associated with significant morbidity and mortality. Given the availability of simple diagnostic methods and the known benefits of strict glycemic control, patients should be screened frequently after organ transplantation. The management of NODAT is multifaceted and aimed at both treatment and prevention of complications. Evaluation of patient risk for post-transplant diabetes mellitus and its complications is an important consideration in initial selection and subsequent modification of the immunosuppressive regimen.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Diabetes Mellitus / etiology*
  • Diabetes Mellitus / immunology
  • Diabetes Mellitus / therapy
  • Graft Survival / immunology
  • Humans
  • Immunosuppression / adverse effects
  • Immunosuppression / methods
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / immunology
  • Male
  • Middle Aged

Substances

  • Immunosuppressive Agents